Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03066778
Title A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung small cell carcinoma

Therapies

Cisplatin + Etoposide

Cisplatin + Etoposide + Pembrolizumab

Carboplatin + Etoposide + Pembrolizumab

Carboplatin + Etoposide

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.